The next decade of healthcare will be shaped not only by scientific breakthroughs, but by our ability to make those breakthroughs accessible to the patients who need them most. This challenge is becoming increasingly urgent as chronic diseases continue to rise globally, emphasizes Dr. Cyrus Karkaria, President - Biotechnology Business, Lupin.
Non-communicable diseases, including metabolic diseases, cancer, diabetes and chronic respiratory diseases, now account for more than 43 million deaths annually, representing nearly 75 per cent of all global deaths. At the same time, biologics have emerged as some of the most effective therapies for treating complex and chronic conditions, transforming outcomes across oncology, immunology, ophthalmology and rare diseases.
Yet access remains uneven. The high cost of biologic therapies continues to place a significant burden on patients, healthcare systems and public health budgets. As healthcare demands grow, the conversation must evolve beyond scientific innovation alone toward sustainable access.
This is where biosimilars assume a far greater role. They are no longer simply lower-cost alternatives. They are strategic enablers of healthcare access, affordability and system sustainability. Built on rigorous science, robust analytics and stringent regulatory standards, biosimilars have the potential to expand access to advanced therapies while helping healthcare systems manage the growing economic pressures of chronic disease.
Scientific Innovation: Driving the Next Generation of Biosimilars
Biosimilars have moved beyond the stage of proving equivalence. Their clinical value is well established. The imperative today is to translate that scientific confidence into wider adoption, enabling healthcare systems to expand access while managing the growing burden of chronic disease.
Several forces are driving this shift. The growing burden of chronic diseases, increasing reliance on biologics across therapeutic areas and mounting pressure on healthcare budgets have created a compelling need for more affordable treatment options. At the same time, advances in analytical characterization, molecular biology, process development and data-driven R&D are enabling biosimilar developers to establish comparability with unprecedented precision.
Scientific progress has significantly strengthened the biosimilar development paradigm. Enhanced analytical tools, platform technologies and deeper understanding of biologic molecules are helping developers achieve greater efficiency without compromising quality, safety or efficacy.
India is well positioned to benefit from this evolution. With one of the world's most active biosimilar ecosystems, the country has built substantial capabilities in biologics development, manufacturing and regulatory execution. This progress reflects not only cost competitiveness, but also growing scientific expertise and the ability to develop complex biologic products for global markets.
However, the next phase of growth will be driven as much by trust as by technology. Robust evidence generation, physician confidence, patient awareness and real-world clinical experience will determine the pace of adoption. Scientific innovation does not end with product development; it must translate into confidence, acceptance and scale.
India's Opportunity to Lead Global Biosimilars Ecosystem
In the last decade, India's BioEconomy has grown to over US$195 billion, supported by biotechnology research, biologics manufacturing, skilled scientific talent, innovation clusters and growing regulatory capabilities. Together, these strengths give India a platform to move beyond participation and build global leadership in affordable biologics.
For India, the opportunity is not simply to produce more biosimilars. It is to build a trusted biotechnology ecosystem that combines scientific depth, manufacturing precision, regulatory discipline and global partnerships. In biosimilars, scale alone is not sufficient. Success depends on consistency, reproducibility and uncompromising quality. Every process, every batch and every regulatory submission must be supported by rigorous science and operational excellence.
The global environment is also becoming more conducive to biosimilar development. Regulatory agencies are increasingly leveraging advances in analytical science to streamline development pathways while maintaining high standards for quality and patient safety. For Indian biotechnology companies, this presents an opportunity to accelerate access to regulated markets while demonstrating global standards of excellence.
If India continues to invest in innovation, talent development, advanced manufacturing and international partnerships, it can play a pivotal role in addressing one of healthcare's most pressing challenges: expanding access to advanced therapies without compromising trust.
Building Trust through Science, Regulation and Real-World Evidence
The long-term success of biosimilars depends on one critical factor: confidence. That confidence must be earned through rigorous science, robust regulatory oversight, transparent communication and continuous evidence generation. Strong analytical characterization, comprehensive comparability assessments, and scientifically sound regulatory frameworks are fundamental to maintaining trust among physicians, patients and payers.
Pharmacovigilance will become even more important as biosimilar adoption expands across broader patient populations and treatment settings. Continuous monitoring of safety, immunogenicity and long-term outcomes provides the reassurance required for sustained adoption. Real-world evidence also has a growing role to play. While clinical studies establish biosimilarity, real-world data demonstrates performance in routine clinical practice and helps build confidence among healthcare providers and decision-makers.
Equally important is education. Misconceptions around biosimilars continue to exist in some markets, particularly concerns that lower cost may imply lower quality or compromised outcomes. Addressing these perceptions through evidence-based engagement will be essential.
The Road Ahead: Innovation Must Scale with Healthcare Needs
The impact of biosimilars is already evident. Across healthcare systems, biosimilar competition has helped generate substantial savings, creating opportunities to expand patient access and redirect resources toward diagnosis, infrastructure, preventive care and future innovation. When medicine costs come down, more patients can be treated, reimbursements can improve, and resources can be redirected toward earlier diagnosis, infrastructure and future innovation.
For India, this presents both an economic opportunity and a healthcare responsibility. By combining scientific innovation, world-class manufacturing, regulatory excellence and global partnerships, India can strengthen its position as a trusted supplier of affordable biologics and biosimilars to the world. Ultimately, their true impact will not be measured by the number of approvals secured or products launched, but by the number of patients who gain access to life-changing therapies that were previously beyond reach.
The future of biosimilars will be shaped by those who can combine science with scale, innovation with access, and affordability with trust. If we can achieve that balance, biosimilars will do more than reshape markets. They will help redefine the future of equitable and sustainable healthcare.
This op-ed was first published in Pharma Bio World (print) on July 31, 2026.
